Previous Article | Next Article ![]()
Journal of Virology, December 2000, p. 11008-11016, Vol. 74, No. 23
Aaron Diamond AIDS Research Center, The
Rockefeller University, New York, New York
100161; Beth Israel Deaconess Medical
Center, Harvard Medical School, Boston, Massachusetts
022152; and Department of
Pediatrics, Tulane University Medical Center, New Orleans, Louisiana
701123
Received 11 May 2000/Accepted 1 September 2000
We investigated the underlying mechanism by which the highly
conserved N-terminal V3 loop glycan of gp120 conferred resistance to
neutralization of human immunodeficiency virus type 1 (HIV-1). We find
that the presence or absence of this V3 glycan on clade A and B viruses
accorded various degrees of susceptibility to neutralization by
antibodies to the CD4 binding site, CD4-induced epitopes, and chemokine
receptors. Our data suggest that this carbohydrate moiety on gp120
blocks access to the binding site for CD4 and modulates the chemokine
receptor binding site of phenotypically diverse clade A and clade B
isolates. Its presence also contributes to the masking of CD4-induced
epitopes on clade B envelopes. These findings reveal a common mechanism
by which diverse HIV-1 isolates escape immune recognition. Furthermore,
the observation that conserved functional epitopes of HIV-1 are more
exposed on V3 glycan-deficient envelope glycoproteins provides a basis
for exploring the use of these envelopes as vaccine components.
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The N-Terminal V3 Loop Glycan Modulates the
Interaction of Clade A and B Human Immunodeficiency Virus Type 1 Envelopes with CD4 and Chemokine Receptors
*
Corresponding author. Mailing address: Aaron Diamond
AIDS Research Center, The Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016. Phone: (212) 448-5000. Fax: (212) 448-5159. E-mail: cmayer{at}adarc.org.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|